4SC AG 2021 AR2
The report highlights 4SC's progress in 2021 as a clinical-stage biopharmaceutical company, focusing on its core oncology programs, resminostat and domatinostat. Key achievements included reaching the recruitment target in the pivotal RESMAIN study for resminostat and signing a settlement agreement with Immunic that provided USD 17.25 million in non-dilutive financing. In early 2022, the company decided to discontinue the domatinostat program to focus resources entirely on resminostat. Financially, 4SC reported revenues of EUR 14.01 million and a net loss of EUR 10.17 million, with cash and cash equivalents of EUR 10.11 million at the end of 2021.
Company: 4SC AG
Sector: Manufacturing
Country: Germany
Year: 2021
Type: AR2
Pages: 88
Back to company
4SC AG
Annual Report
The report highlights 4SC's progress in 2021 as a clinical-stage biopharmaceutical company, focusing on its core oncology programs, resminostat and domatinostat. Key achievements included reaching the recruitment target in the pivotal RESMAIN study for resminostat and signing a settlement agreement with Immunic that provided USD 17.25 million in non-dilutive financing. In early 2022, the company decided to discontinue the domatinostat program to focus resources entirely on resminostat. Financially, 4SC reported revenues of EUR 14.01 million and a net loss of EUR 10.17 million, with cash and cash equivalents of EUR 10.11 million at the end of 2021.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees